Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Guardant Health (Nasdaq: GH) announced upcoming presentations at the San Antonio Breast Cancer Symposium (SABCS) 2024, showcasing research on their liquid biopsy tests and AI analytics. The company will present eight posters, including a spotlight presentation on the Guardant Reveal test, which investigates circulating tumor DNA (ctDNA) dynamics in breast cancer treatment.
The research suggests that ctDNA analysis could help predict endocrine therapy sensitivity and long-term outcomes in HR+ breast cancer. The presentations will cover various topics including molecular profiling, minimal residual disease testing, and real-world data analysis using Guardant's products such as GuardantINFORM, Guardant Infinity, Guardant360 CDx, and Guardant Reveal.
Guardant Health (Nasdaq: GH) ha annunciato le presentazioni in arrivo al San Antonio Breast Cancer Symposium (SABCS) 2024, evidenziando la ricerca sui loro test di biopsia liquida e sull'analisi AI. L'azienda presenterà otto poster, inclusa una presentazione di alto profilo sul test Guardant Reveal, che esplora la dinamica del DNA tumorale circolante (ctDNA) nel trattamento del cancro al seno.
La ricerca suggerisce che l'analisi del ctDNA potrebbe aiutare a prevedere la sensibilità alla terapia endocrina e i risultati a lungo termine nel cancro al seno HR+. Le presentazioni copriranno vari argomenti tra cui il profiling molecolare, il testing della malattia residua minima e l'analisi dei dati reali utilizzando i prodotti di Guardant come GuardantINFORM, Guardant Infinity, Guardant360 CDx e Guardant Reveal.
Guardant Health (Nasdaq: GH) anunció presentaciones próximas en el Simposio de Cáncer de Mama de San Antonio (SABCS) 2024, mostrando investigaciones sobre sus pruebas de biopsia líquida y analíticas de IA. La empresa presentará ocho pósteres, incluida una presentación destacada sobre la prueba Guardant Reveal, que investiga la dinámica del ADN tumoral circulante (ctDNA) en el tratamiento del cáncer de mama.
La investigación sugiere que el análisis de ctDNA podría ayudar a predecir la sensibilidad a la terapia endocrina y los resultados a largo plazo en cáncer de mama HR+. Las presentaciones abarcarán varios temas, incluidos el perfil molecular, las pruebas de enfermedad residual mínima y el análisis de datos del mundo real utilizando productos de Guardant como GuardantINFORM, Guardant Infinity, Guardant360 CDx y Guardant Reveal.
Guardant Health (Nasdaq: GH)는 2024년 샌안토니오 유방암 심포지엄(SABCS)에서 액체 생검 테스트 및 AI 분석에 대한 연구를 발표할 예정이라고 발표했습니다. 이 회사는 Guardant Reveal 테스트에 대한 주목받는 발표를 포함하여 총 8개의 포스터를 발표할 것입니다. 이 테스트는 유방암 치료에서 순환 종양 DNA(ctDNA) 동태를 조사합니다.
연구에 따르면 ctDNA 분석이 호르몬 수용체 양성(HR+) 유방암에서 내분비 요법 감수성과 장기적인 결과를 예측하는 데 도움이 될 수 있다는 것을 시사합니다. 발표에서는 GuardantINFORM, Guardant Infinity, Guardant360 CDx, Guardant Reveal과 같은 Guardant의 제품을 사용한 분자 프로파일링, 최소 잔여 질병 테스트 및 실제 데이터 분석 등 다양한 주제를 다룰 것입니다.
Guardant Health (Nasdaq: GH) a annoncé des présentations à venir lors du San Antonio Breast Cancer Symposium (SABCS) 2024, mettant en avant des recherches sur ses tests de biopsie liquide et ses analyses d'IA. L'entreprise présentera huit affiches, y compris une présentation phare sur le test Guardant Reveal, qui étudie la dynamique de l'ADN tumoral circulant (ctDNA) dans le traitement du cancer du sein.
Les recherches suggèrent que l'analyse du ctDNA pourrait aider à prédire la sensibilité à la thérapie endocrinienne et les résultats à long terme dans le cancer du sein HR+. Les présentations couvriront divers sujets, notamment le profilage moléculaire, le test de maladie résiduelle minimale et l'analyse des données réelles en utilisant les produits de Guardant tels que GuardantINFORM, Guardant Infinity, Guardant360 CDx et Guardant Reveal.
Guardant Health (Nasdaq: GH) gab die kommenden Präsentationen beim San Antonio Breast Cancer Symposium (SABCS) 2024 bekannt, in denen Forschung zu ihren flüssigen Biopsietests und KI-Analysen vorgestellt wird. Das Unternehmen wird acht Poster präsentieren, darunter eine Spotlight-Präsentation über den Test Guardant Reveal, der die Dynamik der zirkulierenden Tumor-DNA (ctDNA) in der Behandlung von Brustkrebs untersucht.
Die Forschung legt nahe, dass die Analyse von ctDNA helfen könnte, die Empfindlichkeit gegenüber endokriner Therapie und langfristige Ergebnisse bei HR+ Brustkrebs vorherzusagen. Die Präsentationen werden verschiedene Themen abdecken, darunter molekulare Profilierung, Tests auf minimale Resterkrankung und die Analyse realer Daten unter Verwendung von Guardants Produkten wie GuardantINFORM, Guardant Infinity, Guardant360 CDx und Guardant Reveal.
- Research indicates potential for ctDNA analysis to predict therapy outcomes and guide treatment decisions
- Company expanding presence in breast cancer diagnostics market with multiple product applications
- None.
Spotlight presentation using Guardant Reveal™ test suggests ctDNA has potential to predict sensitivity to endocrine therapy and long-term outcomes in HR+ breast cancer
Guardant and its research partners will present eight posters, including an SABCS Poster Spotlight featuring the use of the Guardant Reveal test, a tissue-free epigenomic assay, to investigate the dynamics of circulating tumor DNA (ctDNA) during neoadjuvant endocrine therapy in HR+ early breast cancer. Study findings suggest that ctDNA has the potential to provide valuable insights into tumor burden, sensitivity to endocrine therapy, and the emergence of endocrine resistance mutations. The investigators conclude that ctDNA could be a valuable tool in predicting long-term outcomes and in tailoring treatment approaches.
“Working together with our research collaborators, we continue to establish the important role of Guardant’s precision oncology portfolio in informing treatment selection and monitoring for recurrence and therapeutic response,” said Craig Eagle, M.D., chief medical officer at Guardant Health. “We look forward to sharing new studies at SABCS that show how Guardant is working with researchers and cancer care teams to improve outcomes for people living with breast cancer.”
Guardant Health and collaborator poster presentations at SABCS 2024
Wednesday, December 11 | 7:00-8:30 am | Hemisfair Ballroom 1-2 |
||
Abstract |
Title |
Product |
PS7-05
|
SABCS Poster Spotlight Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC) |
GuardantINFORM™ |
Wednesday, December 11 | 12:30 - 2:00 pm | Halls 2-3 |
||
P1-01-24 |
Genomic comparison of rapid vs. typical progressors on CDK4/6 inhibitor treatment in advanced breast cancer |
GuardantINFORM |
P1-05-30 |
A statistical model for integration of on-treatment circulating tumor DNA dynamics and prediction of outcomes in patients with ER+/HER2- metastatic breast cancer |
Guardant Infinity™ |
P1-10-05 |
Real-world molecular profiling after CDK4/6 inhibition in advanced breast cancer: analysis of the SOLTI-1903 HOPE study |
Guardant360® CDx
|
Wednesday, December 11 | 5:30-7:00 pm | Halls 2-3 |
||
P2-05-20 |
Tissue-free minimal residual disease testing in 2,000 consecutive patients with breast cancer: real-world data and case report |
Guardant Reveal |
Thursday, December 12 | 7:00-8:30 am | Stars at Night 3-4 |
||
PS9-04 |
SABCS Poster Spotlight Evaluating racial genomic differences in de novo metastatic breast cancer utilizing ctDNA: results from a large multi-center consortium |
Guardant360 |
PS9-08 |
SABCS Poster Spotlight Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC) |
Guardant Reveal |
Thursday, December 12 | 5:30-7:00 pm | Halls 2-3 |
||
P4-01-19 |
Clinical impact of MRD detection via ctDNA tumor-agnostic assay in early-stage breast cancer patients: a real-world experience |
Guardant Reveal |
The full abstracts for Guardant Health and a list of all abstracts being presented at SABCS 2024 can be found on the SABCS website.
For information and updates from the conference, visit booth 1424 and follow Guardant Health on LinkedIn, X (Twitter) and Facebook.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241209978973/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What will Guardant Health present at SABCS 2024?
What is the main finding of Guardant Health's Reveal test research?
When and where will the SABCS 2024 conference take place?
